Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence

• मुख्य लेखकों: Celia Posada (लेखक), Ángeles Flórez (लेखक), Ana Batalla (लेखक), Juan José Alcázar (लेखक), Daniel Carpio (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Karger Publishers, 2011-02-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Adalimumab is a fully human monoclonal anti-tumor necrosis factor-α agent that is approved for the treatment of Crohn's disease. It has a good safety profile, injection site reactions being the most common adverse effect. We report a case of a 54-year-old woman with a 30-year history of Crohn&#...